Carbamic Acid

Carbamic Acid

SCHEMBL21617652

NC(=O)O.O=C(O)NC1CC=CCC1

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
ESR2 Q92731 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA7 P43166 1/20 0.30
CA9 Q16790 1/20 0.30
CA14 Q9ULX7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL468211 0.94 ALDH1A1 (0.38) ALDH1A1KDM4ELMNATP53TSHR
SCHEMBL825500 0.94 ALDH1A1 (0.38) ALDH1A1KDM4ELMNATP53TSHR
SCHEMBL7369842 0.94 ALDH1A1 (0.38) ALDH1A1KDM4ELMNATP53TSHR
SCHEMBL27976966 0.84 ALDH1A1 (0.34) ALDH1A1KDM4ELMNATP53TSHR
SCHEMBL460381 0.83 ALDH1A1 (0.37) ALDH1A1KDM4ESMN1; SMN2MEN1MAPT
SCHEMBL1960138 0.79
SCHEMBL13856906 0.76 ALDH1A1 (0.34) ALDH1A1ALOX15
SCHEMBL14789368 0.76 ATM (0.42) ALDH1A1KDM4ELMNATP53TSHR
SCHEMBL11161552 0.76 ATM (0.42) ALDH1A1KDM4ELMNATP53TSHR
SCHEMBL28110628 0.73 MAPT (0.47) ALDH1A1KDM4ELMNATP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018121-A1 NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMCIAL DIVERSITY CENTER, INC. (US) 2024-01-18 US disclosed
EP-3820574-A1 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES Novartis AG (CH) 2021-05-19 EP disclosed
WO-2020012337-A1 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES NOVARTIS AG (CH) 2020-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018121-A1 NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE ERG28, CYP51A1, MANBA ALDH1A1 1109/4885KDM4E 3188/4885LMNA 3906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.